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ABSTRACT
Primary immune thrombocytopenia (ITP) is an autoimmune disorder 
characterized by the decrease in peripheral blood platelet count below 100 
x 109/L, and an increased bleeding risk when thrombocytopenia drops below 
30 x 109/L. The mechanisms leading to ITP in adults, although not completely 
elucidated, involves an imbalance between effector and regulatory cells 
that results in a breakdown of the immune tolerance. Autoantibodies are 
considered the main responsible for thrombocytopenia, although direct T-cell 
cytotoxic effect and lysis by Complement attachment and activation could also 
contribute to platelet elimination from circulation. In addition to increased 
peripheral clearance, abnormalities in platelet production also favors platelet 
count reduction. This review is intended to describe some specific knowledge 
about peripheral and bone marrow mechanisms leading to thrombocytopenia 
in adult ITP.
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Primary immune thrombocytopenia (ITP) is an acquired 
autoimmune disorder characterized by chronic isolated low platelet 
count (<100 x 109/L)1, triggered by a loss of the immunological system 
equilibrium that tips the balance toward autoimmunity. Although 
in the last years the pathophysiology of ITP has been intensively 
studied, this field still remains incompletely understood2,3. Another 
significant feature of ITP is the heterogeneity observed among 
patients, concerning not only their clinical profile but also their 
response to treatment, with a small proportion of patients classified 
as refractory4. This heterogeneity is likely due to the participation 
of multiple pathophysiological contributing mechanisms, affecting 
individual patients in different degrees. 
The presence of autoantibodies targeting platelet surface 
glycoprotein(s) (GP) has been demonstrated in patients with ITP 
with percentages of patients with positive autoantibodies varying 
according to different case series5-7. Most of these antibodies are IgG, 
but IgM and IgA can also be detected, usually in association with IgG8. 
Main autoantibody targets are GPIIbIIIa (integrin αIIbβ3), GPIbIX 
and GPIaIIa complex, but, autoantibodies against other GPs (i.e. the 
vitronectin receptor, integrin αvβ3)9, against thrombopoietin and/or 
its receptor c-Mpl10-12 were also detected in some patients. Therefore, 
humoral immunity has been classically considered the main cause of 
thrombocytopenia, although other mechanisms such as direct T-cell 
cytotoxic effect could contribute to platelet elimination as well13,14. 
In addition, Complement activation/fixation capacity is enhanced 
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in plasma samples from ITP15,17. Indeed, Complement-
mediated platelet destruction has been pointed as another 
mechanism of platelet elimination, mainly triggered by 
anti-platelet autoantibodies, but also observed in some ITP 
patients with no-detectable autoantibodies18. 
This review summarizes mechanisms leading to 
thrombocytopenia in ITP with special focus on peripheral 
platelet destruction and impaired platelet production.
Increased circulating platelet clearance
The first and most commonly accepted mechanism 
of platelet clearance in ITP is the binding of anti-platelet 
autoantibodies to their antigenic glycoprotein targets that 
leads to platelet elimination by monocytes/macrophages 
of the reticuloendothelial system through FcγRIIA and 
FcγRIIIA-mediated recognition, mainly in the spleen and 
liver19. However, additional pathological mechanisms 
including platelet apoptosis and loss of sialic acid from 
platelet membrane glycoproteins were described in recent 
years, that also contribute to platelet clearance from 
circulation. 
Increased platelet apoptosis in ITP
Several studies have demonstrated the contribution 
of platelet apoptosis to ITP pathogenesis. Winkler and 
col20 showed evidence of platelet apoptosis, including 
caspase 3, 8 and 9 activation, in children with acute ITP, 
which was ameliorated by intravenous immunoglobulin 
infusion. Concerning adult chronic ITP, increased platelet 
phosphatidylserine (PS) exposure, as a marker of platelet 
apoptosis was shown by Catani21 and Alvarez Román22.
In 2016, our group described increased mitochondrial 
membrane depolarization, active caspase 3 and membrane 
exposure of PS in platelets from ITP, as markers of apoptosis, 
while basal platelet activation assessed by PAC-1 binding 
and P-selectin externalization was ruled out as another 
possible cause of increased PS expression23. Later, Deng and 
col24 confirmed these results and showed higher expression 
levels of the proapoptotic molecules Bak and Bax, while 
the antiapoptotic factor Bcl-xL was decreased. Moreover, 
the same group demonstrated dysregulation of certain 
microRNAs related to apoptosis in platelets from ITP25. 
Cells expressing PS on their membrane are known to be 
cleared through scavenger receptors in macrophages, 
thus, apoptotic platelets would also be eliminated from 
circulation by this mechanism. In our cohort of ITP, the 
inverse relationship found between apoptotic variables 
and peripheral platelet counts, further reinforces the 
relevance of platelet apoptosis in the development of 
thrombocytopenia in this disorder. Interestingly, platelet 
apoptosis was observed in all ITP patients carrying auto-
antibodies against the glycoproteins GPIIbIIIa and GPIbIX, 
but was absent in those patients expressing anti-GPIaIIa 
autoantibodies, suggesting a causal role for these specific 
antibodies in triggering this phenomenon.
In this study, PS externalization was not noticed in 
normal platelets incubated with ITP plasmas but it could be 
observed by adding normal autologous CD3+ lymphocytes 
to this system, suggesting an antibody-dependent cytotoxic 
effect. In the same system, anti-platelet antibodies-depleted 
ITP plasma had no effect on normal platelet apoptosis, 
while the IgG fraction of ITP plasma retained the apoptotic 
effect observed when whole plasma was used, confirming 
the involvement of auto-antibodies in the induction of 
apoptosis. 
Interestingly, recent work described that autophagy 
is decreased in platelets from ITP26 and suggested this 
reduction could be linked to increased platelet apoptosis. 
Further studies are warranted to elucidate the interplay 
between autoantibodies, autophagy and apoptosis in this 
disorder. 
Increased loss of sialic acid from platelet glycoproteins 
in ITP
In 2015, Li and col.27 described for the first time 
that plasma from ITP patients containing anti-GPIbIX 
autoantibodies induced loss of sialic acid capping 
carbohydrates from platelet glycoproteins. This mechanism 
is triggered by the ability of these autoantibodies to 
induce platelet activation, which promote neuraminidase 
externalization, the ultimate responsible for sialic acid 
cleavage from membrane glycoproteins. Platelets bearing 
asialoglycoproteins on their membrane are clarified in 
the liver by cooperation between macrophage galactose 
lectin (MGL) and the C-type lectin receptor CLEC4F, both 
expressed on Kupffer cells, and Ashwell-Morell receptor 
(AMR) in hepatocytes, as demonstrated by studies 
performed in mice28,29. In addition, activation of the JAK2/
STAT3 pathway downstream AMR after asialoglycoprotein 
binding, has been pointed as the mechanism triggering 
synthesis of thrombopoietin (Tpo), the main growth factor 
of the megakaryocytic lineage30. 
In a recent study, our group investigated several 
possible causes of thrombocytopenia in a cohort of ITP 
patients, including platelet desialylation. Results showed 
that loss of sialic acid from normal platelet glycoproteins 
occurs not only in the presence of anti-GPIbIX but also anti-
GPIIbIIIa ITP autoantibodies, as assessed by the increase 
in Ricinus communis agglutinin I (RCA-I), recognizing 
galactosyl (β-1,4) N-acetylglucosamine (Galβ4GlcNAc) 
and Peanut agglutinin (PNA) which recognizes galactosyl 
(β-1,3) N-acetylgalactosamine (Galβ3GalNAc), both 
exposed after sialic acid loss. In addition, desialylation 
could be concomitantly observed with platelet apoptosis, 
although this was not a mandatory association31. Recently, 
Manzano and col reported increased apoptosis and loss of 
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sialic acid in platelets from non-responsive ITP patients32. 
Interestingly, although a direct correlation was found 
between caspase activation and desialylation in the whole 
population included in the study (ITP patients who did 
not need treatment for at least six months, ITP patients 
responding to agonists of thrombopoietin receptors, 
and non-responders), levels of caspase activity between 
non-responders and thrombopoietin receptor agonists-
responders were not different, supporting the notion that 
apoptosis and desialylation are not necessarily related. 
In addition, decreased platelet surface glycans in non-
responders ITP patients was accompanied by a decrease 
in T regulatory lymphocyte population suggesting a link 
between this platelet abnormality and immune imbalance.
The observation that anti-GPIIbIIIa autoantibodies can 
also induce loss of sialic acid from platelet glycoproteins 
was recently confirmed by Marini and col33. By blocking the 
FcγRIIA signaling, authors demonstrated that sialic acid 
loss is at least partially due to crosslinking of anti-GPIIbIIIa 
autoantibodies to FcγRIIA, which is responsible for the 
release of sialidase from the intracellular compartments of 
platelets. 
Concerning circulating Tpo levels in ITP, it was suggested 
that they were lower than expected for the degree of 
thrombocytopenia34. In the late ́ 90s, when Tpo synthesis by 
the liver was supposed to be constant, the cumulative mass 
of megakaryocytes and platelets were considered as the 
main determinant of Tpo levels35,36.  Nowadays, assuming 
that binding of desialylated platelets to hepatic AMR is, at 
least in part, responsible for Tpo synthesis, differences in 
platelet desialylation levels among patients with ITP and 
the fact that some of them do not display increased platelet 
desialylation, could account for variations in Tpo levels 
among patients population. The influence of desialylation 
in modulating circulating Tpo levels in ITP should be 
tested by comparing these variables in a large ITP cohort. 
In addition, other factors such as platelet GPIbα were 
described to regulate hepatic Tpo homeostasis37. In this 
regard, ITP autoantibodies targeting this glycoprotein 
could interfere with this mechanism. Therefore, further 
investigations are needed to fully understand the regulation 
of Tpo synthesis in ITP as well as in physiologic conditions. 
Impaired platelet production
Platelet production is the final step of a complex 
series of events involving two well defined processes: 
megakaryopoiesis and thrombopoiesis. Megakaryopoiesis 
initiates when undifferentiated CD34+ hematopoietic 
progenitor commits to the megakaryocytic lineage and ends 
when megakaryocytes reach their full maturational state. 
Next, the process identified as thrombopoiesis involves 
cytoplasmic megakaryocytic reorganization, proplatelet 
extension and branching and, after these proplatelets go 
through the endothelial bone marrow barrier, platelets are 
released from their tips into the bloodstream.
Megakaryopoiesis in ITP
Early independent works from Chang38 and McMillan39 
studied the effect of the addition of 10% of ITP plasma to 
the culture medium of normal hematopoietic progenitors 
induced to differentiate into megakaryocytes. Their 
results showed that plasma from ITP patients impaired 
megakaryocyte development, pointing to autoantibodies 
directed to GPIbIX and GPIIbIIIa as responsible for this 
effect. Unlike these previous studies that used mononuclear 
cells39 or 20-30% pure CD34+ progenitors38 as source of 
normal hematopoietic precursors, we reproduced these 
experiments using at least 93% pure CD34+ hematopoietic 
progenitors isolated from normal human cord blood. In 
these conditions, megakaryopoiesis was not inhibited 
by ITP samples. Moreover, the expression of CD42b, a 
marker of megakaryocyte maturation, was increased in the 
presence of 45% of the ITP plasmas, while megakaryocyte 
size and ploidy were normal31. These results are in line with 
the known concept that the number of megakaryocytes in 
bone marrow from ITP patients is normal or increased40,41.
Besides, although it was described that circulating 
levels of thrombopoietin are low for the degree of 
thrombocytopenia in ITP, as mentioned before, they seem 
sufficient to maintain a proper megakaryocyte population 
in bone marrow.
Participation of apoptosis during megakaryocyte and 
platelet production
Reports describing apoptosis in the megakaryocytic 
lineage performed on bone marrow samples from ITP 
patients are controversial. Uçar and col42 found no 
differences in the number of megakaryocytes and their 
apoptotic status between ITP and control children; 
Houwerzijl et al43 found ultrastructural abnormalities 
compatible with apoptosis in adult ITP, and a recent 
study described a decrease of megakaryocyte apoptosis 
in bone marrow biopsies of ITP subjects compared to 
healthy controls44. Although these discrepant results are 
intriguing and would encourage researchers to continue 
the investigations, bone marrow samples form ITP are not 
easily available because bone marrow examination is not 
generally needed to diagnose ITP. 
Beyond megakaryopoiesis, data about the participation 
of apoptotic events during normal physiologic proplatelet 
formation and platelet production has also been 
controversial. While several studies support that localized 
apoptotic events are needed for mature megakaryocytes 
to rearrange their cytoplasmic architecture and proceed 
with proplatelet extension and platelet release, more 
recent information hold the notion that apoptosis must be 
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restrained during proplatelet formation, and only when 
platelets have been released, the remaining naked nuclei 
undergoes apoptosis (reviewed by McArthur45).
Similarly, investigations evaluating the effect of ITP 
plasma on mature megakaryocyte apoptosis have led to 
discordant results. Yang et al46 described lower expression 
of tumor necrosis factor-related apoptosis-inducing ligand, 
higher expression of Bcl-xL and lower platelet release 
in normal megakaryocytes incubated with ITP plasma, 
pointing to decreased apoptosis as a contributing factor 
to reduced platelet production. In our hands, normal 
mature megakaryocytes incubated for 48 hours with 10% 
ITP plasma did not suffer caspase 3-7 activation, and the 
number of megakaryocytes displaying nuclear picnosis 
was slightly increased. However, proplatelet formation was 
significantly decreased as will be discussed later47. Then, 
although the number of megakaryocytes in bone marrow 
from ITP is normal or elevated, abnormalities in the 
apoptotic pathways of mature megakaryocytes could not 
be ruled out as possible factors leading to a lower number 
of megakaryocytes capable of producing proplatelets. 
Indeed, further work is necessary to clarify this topic.
Altered megakaryocyte functionality and impaired 
thrombopoiesis
Other important players participating in the proper 
functionality of megakaryocytes are extracellular matrix 
proteins present in the bone marrow milieu. Megakaryocyte 
interaction with different matrix proteins play specific 
roles in megakaryocytic physiology.  Two of these essential 
molecules present in the vascular niche are fibrinogen 
and von Willebrand factor (vWf). Main receptors for these 
ligands are GPIIbIIIa, which binds both proteins, and GPIbIX, 
that recognizes vWf. In addition to their key role in platelet 
function, GPIIbIIIa and GPIbIXV complexes are involved 
in megakaryocyte development and platelet production. 
Proof of their participation in these events are the deep 
abnormalities observed in macrothrombocytopenia due 
to mutations leading to partial activation of GPIIbIIIa48, 
and mutations in GPIbIXV, responsible for Bernard-Soulier 
syndrome 49.
Grodzielski and col50 demonstrated that plasma and 
specifically the IgG fraction from ITP patients interfere 
with adhesion and spreading of megakaryocytes. 
This interference is specific for each receptor-ligand 
pair depending on the type of autoantibody present. 
Anti-GPIIbIIIa autoantibodies inhibit megakaryocytic 
interaction with fibrinogen, reducing adhesion, spreading 
and signal transduction downstream this receptor, as 
demonstrated by decreased β3 subunit phosphorylation. 
Abnormal glycoprotein function was also observed by 
impaired PAC-1 binding to megakaryocytes incubated with 
ITP plasmas bearing these autoantibodies47. Similarly, anti-
GPIbIX autoantibodies impair megakaryocyte adhesion 
and spreading to vWf, and preclude Src phosphorylation 
downstream this receptor. 
The main raison détre of megakaryocytes is platelet 
production, and, as a consequence of autoantibody binding 
to GPIIbIIIa and/or GPIbIX complexes, proplatelet formation 
is inhibited 47,51. The participation of autoantibodies in 
abnormal thrombopoiesis was proved by reproducing the 
inhibitory effect of ITP plasma using purified IgG, and by 
its reversion when ITP plasma was immunodepleted from 
autoantibodies by incubation with normal platelets.
In addition to the decrease in the number of 
megakaryocytes producing proplatelets, morphological 
changes were observed in the architecture of proplatelets 
generated in the presence of ITP plasma. Most of the 
patient´s samples induced wider and shorter proplatelets, 
bearing lower numbers of bifurcation points and tips, 
and overall, less complex than those observed when 
megakaryocytes were cultured with the addition of normal 
plasma47. Considering that megakaryocytes must elongate 
their proplatelets through the bone marrow endothelial 
barrier in order to release platelets into the bloodstream, 
these morphological proplatelet features could hinder 
thrombopoiesis. Altogether, these results could imply 
that, in addition to the lower number of megakaryocytes 
capable of producing proplatelets in ITP, each proplatelet-
bearing megakaryocyte would be unable to produce a 
proper number of platelets.
The osteoblastic niche of bone marrow is a type I 
collagen-enriched environment. Megakaryocyte binding 
to collagen through GPIaIIa complex inhibits proplatelet 
production52, precluding premature platelet release within 
this compartment. Our in vitro experiments demonstrated 
that plasma and purified IgG fractions from ITP patients 
containing anti-GPIaIIa autoantibodies, induced a 
decrease in megakaryocyte adhesion and spreading on 
type I collagen along with lower MLC2 phosphorylation 
downstream GPIaIIa50. In agreement with the fact that MLC2 
phosphorylation is a key downstream effector mediating 
GPIaIIa-induced negative regulation of thrombopoiesis53, 
these autoantibodies interfered with normal inhibition 
of proplatelet formation on type I collagen, allowing 
megakaryocytes to extend proplatelets even on a type 
I collagen-coated surface47. These findings suggest that 
the presence of anti-GPIaIIa autoantibodies could lead to 
premature proplatelet production in the osteoblastic niche, 
hindering platelet release within the bloodstream. 
Along with these abnormalities, Zeng and col.54 added 
autoantibodies targeting the vitronectin receptor, to the 
list of factors responsible for the interference between 
megakaryocyte adhesion to the vascular niche, and 
potentially contributing to impair platelet production in ITP.
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In addition to platelets, megakaryocyte glycoproteins 
are also target for autoantibody desialylation. Unlike what 
was observed in platelets, loss of sialic acid from normal 
megakaryocytes was only found in the presence of ITP 
plasma containing anti-GPIbIX autoantibodies31. Marini 
and col.33 demonstrated that desialylation induced by ITP 
autoantibodies (either anti GPIIbIIIa or GPIbIX) inhibits 
megakaryocyte adhesion to the bone marrow extracellular 
matrix proteins fibrinogen and vWf, leading to limited cell 
differentiation and reduced ability to extend proplatelets. 
Thus, besides increasing platelet clearance, desialylation 
has also been established as a mechanism of impaired 
platelet production.  
Overall, these studies demonstrate that ITP autoantibodies 
mainly affect specific and different intracellular pathways, 
depending on their target proteins, interfering with normal 
megakaryocytic functions within the bone marrow and 
leading to decreased platelet production.
Conclusions 
The growing amount of knowledge concerning 
pathophysiological abnormalities in ITP and results that 
evaluated several of these mechanisms in individual 
patients, show that mechanisms of thrombocytopenia are 
multifactorial, and frequently involve concomitant defects 
in platelet production and clearance. One of the main 
conclusions of our work concerning platelet production 
is that ITP autoantibodies are more harmful on inhibiting 
thrombopoiesis than affecting megakaryopoiesis. 
Regarding platelet clearance, apart from the classical Fc-
dependent mechanism, platelet apoptosis and desialylation 
are additional and independent processes contributing 
to lower platelet count (Figure 1). These findings provide 
a rational for the use of combination therapy, including 
drugs with different mechanisms of action, in patients with 
highly refractory disease.
Figure 1: Mechanisms leading to low platelet count in Immune Thrombocytopenia. 
This graphical abstract includes mechanisms published in references 19, 24, 37 and 40. Impaired platelet production is likely due to 
abnormal megakaryocytic function, including altered interaction with extracellular matrix proteins from bone marrow and thrombopoiesis 
(reduced number of proplatelet-producing megakaryocytes and abnormal proplatelet structure), induced by autoantibody binding to 
megakaryocytic glycoproteins. Although autoantibody-induced abnormalities were also observed during megakaryopoiesis, they seem to 
contribute in lesser extent to the reduction in platelet production. Enhanced peripheral platelet clearance could be related to monocyte/
macrophage phagocytosis induced by binding of platelet-autoantibody complex to Fcγ receptors IIA and IIIA and phosphatidylserine 
expressed on apoptotic platelets that binds to scavenger receptors. In addition, desialylated platelets could be clarified by cooperation 
between Kupffer cells and hepatocytes in the liver. 
Lev PR, Goette NP, Marta RF. Pathophysiological Mechanisms Leading to Low Platelet 
Count in Immune Thrombocytopenia. J Immunological Sci. (2020); 4(2): 1-7 Journal of Immunological Sciences
Page 6 of 7
References
1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization 
of terminology, definitions and outcome criteria in immune 
thrombocytopenic purpura of adults and children: Report from an 
international working group. Blood. 2009; 113: 2386–2393 
2. Li J, Sullivan JA, Ni H. Pathophysiology of immune thrombocytopenia. 
Curr Opin Hematol. 2018; 25: 373-381. 
3. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic 
mechanisms in Immune Thrombocytopenia (ITP). J Clin Med. 2017; 
6: 16.
4. Witkowski M, Witkowska M, Robak T. Autoimmune thrombocytopenia: 
Current treatment options in adults with a focus on novel drugs. Eur J 
Haematol. 2019; 103: 531-541. 
5. Davoren A, Bussel J, Curtis BR, et al. Prospective evaluation of a new 
platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis 
of autoimmune thrombocytopenia (AITP). Am J Hematol. 2005; 78: 
193-197.
6. Stockelberg D, Hou M, Jacobsson S, et al. Detection of Platelet 
antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A 
comparative study using flow cytometry, a whole platelet ELISA, and 
an antigen capture ELISA. Eur J Haematol. 1996; 56: 72-77.
7. McMillan R. Antiplatelet Antibodies in Chronic Immune 
Thrombocytopenia and Their Role in Platelet Destruction and 
Defective Platelet Production. Hematol Oncol Clin N Am. 2009; 23: 
1163–1175.
8. He R, Reid DM, Jones CE, et al. Spectrum of Ig classes, specificities, 
and titers of serum antiglycoproteins in chronic idiopathic 
thrombocytopenic purpura. Blood. 1994; 83: 1024–1032.
9. Kosugi S, Tomiyama Y, Honda S, et al. Anti-alpha(v) beta(3) antibodies 
in chronic immune thrombocytopenic purpura. Thromb Haemost. 
2001; 85: 36–41.
10. Kuwana M, Okazaki Y, Kajihara M, et al. Autoantibody to c-Mpl 
(thrombopoietin receptor) in systemic lupus erythematosus: 
relationship to thrombocytopenia with megakaryocytic hypoplasia. 
Arthritis Rheum. 2002; 46: 2148–2159.
11. Jing FM, Zhang XL, Meng FL, et al. Anti-c-Mpl antibodies in immune 
thrombocytopenia suppress thrombopoiesis and decrease response 
to rhTPO. Thromb Res. 2018; 170: 200-206. 
12. Nazy I, Kelton JG, Moore JC, et al. Autoantibodies to thrombopoietin 
and the thrombopoietin receptor in patients with immune 
thrombocytopenia. Br J Haematol. 2018; 181: 234–241.
13. Olsson B, Andersson PO, Jernas M, et al. T-cell mediated cytotoxicity 
toward platelets in chronic idiopathic thrombocytopenic purpura. Nat 
Med. 2003; 9: 1123-1124.
14. Zhao C, Li X, Zhang F, et al. Increased cytotoxic T-lymphocyte-
mediated cytotoxicity predominant in patients with idiopathic 
thrombocytopenic purpura without platelet autoantibodies. 
Haematologica. 2008; 93: 1428-1430.
15. Tsubakio T, Tani P, Curd JG, et al. Complement activation in vitro 
by antiplatelet antibodies in chronic immune thrombocytopenic 
purpura. Br J Haematol. 1986; 63: 293–300. 
16. Peerschke EIB, Andemariam B, Yin W, et al. Complement activation on 
platelets correlates with a decrease in circulating immature platelets 
in patients with Immune Thrombocytopenic Purpura.  Br J Haematol. 
2010; 148: 638–645. 
17. Ge J, Wang L, Li J, et al. Increase of C3a is associated with hemorrhagic 
propensity in patients with Immune Thrombocytopenia. Clin 
Lab. 2017; 63: 765-771.
18. Najaoui A, Bakchoul T, Stoy J, et al. Autoantibody-mediated 
complement activation on platelets is a common finding in patients 
with immune thrombocytopenic purpura (ITP). Eur J Haematol. 1012; 
88: 167–174. 
19. McMillan R. The pathogenesis of chronic immune thrombocytopenic 
purpura. Semin Hematol. 2007; 44: S3–S11. 
20. Winkler J, Kroiss S, Rand M, et al. Platelet apoptosis in paediatric 
immune thrombocytopenia is ameliorated by intravenous 
immunoglobulin. Br J Haematol. 2012; 156: 508–515. 
21. Catani L, Fagioli ME, Tazzari PL, et al.. Dendritic cells of immune 
thrombocytopenic purpura (ITP) show increased capacity to present 
apoptotic platelets to T lymphocytes. Exp Hematol. 2006; 34: 879–
887. 
22. Alvarez Roman MT, Fernandez Bello I, Arias-Salgado EG, et al. Effects of 
thrombopoietin receptor agonists on procoagulant state in patients with 
immune thrombocytopenia. J Thromb Haemost. 2014; 112: 65– 72.
23. Goette NP, Glembotsky AC, Lev PR, et al. 
Platelet apoptosis in adult immune thrombocytopenia: insights into 
the mechanisms of damage triggered by auto-antibodies. PLoS 
One. 2016; 11(8): e0160563. 
24. Deng G, Yu S, Li Q, et al. Investigation of platelet apoptosis in adult 
patients with chronic immune thrombocytopenia. Hematology. 2017; 
22: 155-161. 
25. Deng G, Yu S, He Y, et al. MicroRNA profiling of platelets from immune 
thrombocytopenia and target gene prediction. Mol Med Rep. 2017; 
16: 2835-2843. 
26. Wang Ch, Ma S, Bi S, et al. Enhancing autophagy protects platelets in 
immune thrombocytopenia patients. Ann Transl Med. 2019; 7: 134.
27. Li J, van der Wal DE, Zhu G, et al. Desialylation is a mechanism of Fc-
independent platelet clearance and a therapeutic target in immune 
thrombocytopenia. Nat Comm. 2015; 6: 7737.
28. Li Y, Fu J, Ling Y, et al. Sialylation on O-glycans protects platelets from 
clearance by liver Kupffer cells PNAS. 2017; 114: 8360-8365
29. Deppermann C, Kratofil RM, Peiseler M, et al. Macrophage galactose 
lectin is critical for Kupffer cells to clear aged platelets. J Exp Med. 
2020. doi.org/10.1084/jem.20190723
30. Grozovsky R, Begonja AJ, Liu K, et al. The Ashwell-Morell receptor 
regulates hepatic thrombopoietin production via JAK2-STAT3 
signaling. Nat Med. 2015; 21: 47–54. 
31. Grodzielski M, Goette NP, Glembotsky AC, et al. Multiple concomitant 
mechanisms contribute to low platelet count in patients with immune 
thrombocytopenia. Sci Rep. 2019; 18: 9:2208. 
32. Monzón Manzano E, Alvarez Román MT, Sanz RJ, et al. Platelet and immune 
characteristics of immune thrombocytopaenia patients non-responsive 
to therapy reveal severe immune dysregulation. Br J Haematol. 2020; 
189: 943-953. Comment by Kapur R. Analysing therapeutic responses 
in Immune Thrombocytopaenia: shifting the focus towards immune 
characteristic. Br J Haematol. 2020; 189: 811-812.
33. Marini I, Zlamal J, Faul C, et al. Autoantibody-mediated desialylation 
impairs human thrombopoiesis and platelet life span. Haematologica. 
2019; pii: haematol.2019.236117.
34. Kosugi S, Kurata Y, Tomiyama Y, et al. Circulating Thrombopoietin Level 
in Chronic Immune Thrombocytopenic Purpura. Br J Haematol. 1996; 
93: 704-6.
35. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels 
are high when thrombocytopenia is due to megakaryocyte deficiency 
and low when due to increased platelet destruction, Blood. 1996; 87: 
4068–4071. 
36. Makar RS, Zhukov OS, Sahud MA, et al. Thrombopoietin levels in 
patients with disorders of platelet production: diagnostic potential 
and utility in predicting response to TPO receptor agonists. Am. J. 
Hematol. 2013; 88: 1041–1044.
Lev PR, Goette NP, Marta RF. Pathophysiological Mechanisms Leading to Low Platelet 
Count in Immune Thrombocytopenia. J Immunological Sci. (2020); 4(2): 1-7 Journal of Immunological Sciences
Page 7 of 7
37. Xu M, Li J, Dias Neves MA, et al. GPIba is required for platelet-mediated 
hepatic thrombopoietin generation. Blood. 2018; 132: 622-634. 
38. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic 
purpura (ITP) plasma and purified ITP monoclonal autoantibodies 
inhibit megakaryocytopoiesis in vitro. Blood. 2003; 102: 887-895.
39. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro 
megakaryocyte production by antiplatelet autoantibodies from adult 
patients with chronic ITP. Blood. 2004; 103: 1364–9.
40. Dameshek W, Miller EB. The megakaryocytes in idiopathic 
thrombocytopenic purpura, a form of hypersplenism. Blood. 1946; 1: 
27–50.
41. Jubelirer SJ, Harpold R. The role of the bone marrow examination in 
the diagnosis of immune thrombocytopenic purpura: case series and 
literature review. Clin Appl Thromb Hemost. 2002; 8: 73-6.
42. Uçar C, Oren H, Irken G, et al. Investigation of megakaryocyte apoptosis 
in children with acute and chronic idiopathic thrombocytopenic 
purpura. Eur J Haematol. 2003; 70: 347–352.
43. Houwerzijl EJ, Blom NR, van der Want JJL, et al. Ultrastructural 
study shows morphologic features of apoptosis and para-apoptosis 
in megakaryocytes from patients with idiopathic thrombocytopenic 
purpura Blood. 2004; 103: 500-506.
44. Vrbensky JR, Nazy I, Toltl LJ, et al. Megakaryocyte apoptosis in immune 
thrombocytopenia. Platelets. 2018; 29(7): 729-732.
45. McArthur K, Chappaz S, Kile BT. Apoptosis in megakaryocytes and 
platelets: life and death of a lineage. Blood. 201; 131: 605-610.
46. Yang L, Wang L, Zhao C, et al. Contributions of TRAIL-mediated 
megakaryocyte apoptosis to impaired megakaryocyte and platelet 
production in immune thrombocytopenia. Blood. 2010; 116: 4307–4316.
47. Lev PR, Grodzielski M, Goette NP, et al. Impaired proplatelet formation 
in immune thrombocytopenia: a novel mechanism contributing to 
decreased platelet count. Br J Haematol. 2014; 165: 854-64.
48. Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B 
R995W mutation inducing constitutive activation of the αIIbβ3 
receptor affects proplatelet formation and causes congenital 
macrothrombocytopenia. Blood. 2011; 117:  5479-5484.
49. Strassel C, Eckly A, Leon C, et al. Intrinsic impaired proplatelet 
formation and microtubule coil assembly of megakaryocytes in a 
mouse model of Bernard-Soulier syndrome. Haematologica. 2009; 
94: 800-810.
50. Grodzielski M, Di Buduo CA, Goette NP, et al. Autoantibodies in 
immune thrombocytopenia affect the physiological interaction 
between megakaryocytes and bone marrow extracellular matrix 
proteins. Br J Haematol. 2018; 183: 319-323. 
51. Iraqi M, Perdomo J, Yan F, et al. Immune thrombocytopenia: antiplatelet 
autoantibodies inhibit proplatelet formation by megakaryocytes and 
impair platelet production in vitro. Haematologica. 2015; 100: 623–
32.
52. Sabri S, Jandrot-Perrus M, Bertoglio J, et al. Differential regulation of 
actin stress fiber assembly and proplatelets formation by alpha2beta1 
integrin and GPVI in human megakaryocytes. Blood. 2004; 104: 
3117–3125.
53. Chang Y, Auradee F, Larbret F, et al. Proplatelet formation is regulated 
by the Rho/ROCK pathway. Blood. 2007; 109: 4229-4236.
54. Zeng DF, Chen F, Wang S, et al. Autoantibody against integrin 
αvβ3 contributes to thrombocytopenia by blocking the migration and 
adhesion of megakaryocytes. J Thromb Haemost. 2018; 16: 1843-
1856.
